Scientific supervisor

Zolotovskaya Marianna

Main place of work:

Moscow Institute of Physics and Technology, Laboratory of Translational and Genomic Bioinformatics

Write to the mail


Professional interests/research projects:

Marianna Arsenovna Zolotovskaya, Researcher, Laboratory of Translational and Genomic Bioinformatics, Moscow Institute of Physics and Technology. An experienced bioinformatician, at the same time a certified oncologist. She was the first to develop a method for quantifying the effect of the total mass of mutations in protein-coding genes on the functioning of molecular pathways (Zolotovskaia et al., Front Oncol. 2019 Jan 4;8:658). Created a method for screening genes-potential molecular targets of anticancer drugs, based on the quantitative assessment of involvement in various molecular processes inside the cell (Zolotovskaia et al., Front Pharmacol. 2019 Jan 23;10:1; Zolotovskaia et al., Methods Mol Biol. 2020; 2063:207-234). First investigated the profiles of genetic and transcriptome changes for 419 molecular pathways on a wide sample (about 5000) of clinically annotated transcription and mutation data (Zolotovskaia et al., Cancers (Basel). 2020 Jan 22;12(2)). Based on the analysis of genetic and expression heterogeneity, she was the first to compare the profiles of clinically recommended targeted drugs and the molecular features of tumors.
Main publications:

  1. Zolotovskaia M, Tkachev V, Sorokin M, Garazha A, Kim E, Kantelhardt SR, Bikar SE, Zottel A, Šamec N, Kuzmin D, Sprang B, Moisseev A, Giese A, Efimov V, Jovčevska I, Buzdin A. Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. Cancers (Basel). 2021 Aug 16;13(16):4117. doi: 10.3390/cancers13164117. PMID: 34439271; PMCID: PMC8394245.
  2. Vladimirova U, Rumiantsev P, Zolotovskaia M, Albert E, Abrosimov A, Slashchuk K, Nikiforovich P, Chukhacheva O, Gaifullin N, Suntsova M, Zakharova G, Glusker A, Nikitin D, Garazha A, Li X, Kamashev D, Drobyshev A, Kochergina-Nikitskaya I, Sorokin M, Buzdin A. DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles. Heliyon. 2021 Mar 13;7(3):e06408. doi: 10.1016/j.heliyon.2021.e06408. PMID: 33748479; PMCID: PMC7970325.
  3. Zolotovskaia MA, Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, Sekacheva MI, Borisov NM, Tkachev VS, Garazha AV, Kaprin AD, Shegay PV, Giese A, Kim E, Roumiantsev SA, Buzdin AA. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. Int J Mol Sci. 2020 Feb 26;21(5):1580. doi: 10.3390/ijms21051580. PMID: 32111026; PMCID: PMC7084891.
  4. Zolotovskaia MA, Tkachev VS, Seryakov AP, Kuzmin DV, Kamashev DE, Sorokin MI, Roumiantsev SA, Buzdin AA. Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer. Cancers (Basel). 2020 Jan 22;12(2):271. doi: 10.3390/cancers12020271. PMID: 31979117; PMCID: PMC7073226.
  5. Zolotovskaia M, Sorokin M, Garazha A, Borisov N, Buzdin A. Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods Mol Biol. 2020;2063:207-234. doi: 10.1007/978-1-0716-0138-9_16. PMID: 31667773.
  6. Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, Buzdin AA. Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Front Oncol. 2019 Jan 4;8:658. doi: 10.3389/fonc.2018.00658. PMID: 30662873; PMCID: PMC6328788.
  7. Zolotovskaia MA, Sorokin MI, Emelianova AA, Borisov NM, Kuzmin DV, Borger P, Garazha AV, Buzdin AA. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Front Pharmacol. 2019 Jan 23;10:1. doi: 10.3389/fphar.2019.00001. PMID: 30728774; PMCID: PMC6351482.
Researcher ID:
Scopus Author ID:
Educational programs
School structure
© 2001-2022 Moscow Institute of Physics and Technology (National Research University)
Social networks
Language version
Site Search